TOPIC HIGHLIGHTS
Designing, Screening and Assessing Selectivity
Identifying and Assaying Allosteric Kinase Inhibitors
Covalent Inhibition
Kinases for CNS Indications – An Exciting Challenge
Inflammation& Autoimmune – Leading Programs
Kinases in Oncology – PI3, mTOR, cMet & More
Novel Kinase Targets in Hot Pursuit
Screening & Monitoring DMPK and Tox
Advances in Computational Methods
Resistance – Future Challenges
Click here for the final agenda
Distinguished Faculty
Mark Ashwell, ArQule Inc
James Blake, Array BioPharma, Inc.
Peter Brandt, Beactica AB
Stephen K. Burley, Eli Lilly & Company
Dirksen Bussiere, Novartis Vaccines & Diagnostics Inc.
Josette Carnahan, Amgen
Kenneth Comess, Abbott Laboratories
Jean Cui, Pfizer, Inc.
Greg Cuny, Brigham & Women’s Hospital
David C. Dalgarno, ARIAD Pharmaceuticals Inc.
David H. Drewry, GlaxoSmithKline
Isabelle Dussault, Amgen
Doriano M. Fabbro, Novartis Institutes for BioMedical Research
Jordan S. Fridman, Incyte Corp.
Daniel Goldberg, Karos Pharmaceuticals, Inc.
Andrew C. Good, Genzyme Corp
John D. Haley, OSI Pharmaceuticals
Stephanos Ioannidis, AstraZeneca
Ronald Knegtel, Vertex Pharmaceuticals (Europe) Ltd.
Ravi G. Kurumbail, Pfizer, Inc.
Chris Liang, Xcovery, LLC
Carol MacKintosh, University of Dundee
Henrik Mobitz, Novartis
Yibing Shan, D. E. Shaw Research
Juswinder Singh, Avila Therapeutics, Inc.
Rajinder Singh, Rigel Pharmaceuticals Inc.
Kent Stewart, Abbott
Eli Wallace, Array BioPharma
Neil Wishart, Abbott
Paul Yu, Massachusetts General Hospital
Donald Zack, Johns Hopkins University School of Medicine
Specialized Panels:
I. Next Generation Kinases –
Selectivity What Now?
II. Structure-Based Kinase
Inhibitor Design
Presented by hand-selected panelists who have contributed more than a decade
of research to the kinase field!
June 6th Half Day
Pre-Conference Short Course:
The Art and Science of Kinases -
What you Need to Know
Kent Stewart, Ph.D. Research Fellow, Abbott
|
Co-Located with:11th Annual Structure-Based Drug Design Conference
June 8-10